The GLP accredited research centre of Venus Remedies, Venus Medicine Research Centre has received patent grant for a novel antibiotic product VRP008 consisting of a carbapenem and a novel amino glycoside (NCE entity) from EPO.
“We, at VMRC, have been working dedicatedly to provide effective and affordable solution to the compounding problem of anti-microbial resistance ever since we recognised this problem more than 10 years ago. The sincerity and hard work of our team is reflected in the patents we have received from all over the globe for our novel antibiotic entities such as elores, potentox, vancoplus and VRP008 (the research code for this AAE),” informed Dr Manu Chaudhary, Joint Managing Director cum Director Research, Venus Remedies.
The product is designed for mixed multi-drug infections for paediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required. It is expected to capture a wide range of market sector which is upheaval with antibiotics for wide indications.
EP News Bureau– Mumbai